Document Type

Review Article


The novel coronavirus (COVID-19) can result in several neurological complications including Guillain-Barré Syndrome (GBS). It is an acute parainfectious paralytic neuropathy. This review summarizes the demographic features, clinical presentation, diagnostics workup, and management strategies of COVID-19 associated GBS reported in the literature. We searched Medline, PubMed Central, SCOPUS, and Google Scholar using pre-defined keywords. We included all kinds of manuscripts in the English language only. Demographics, clinical features, diagnostic workup, management, and outcomes were documented in the datasheet. We identified 24 cases of COVID-19 associated GBS. Most were reported from Italy, followed by the USA. The majority were males (18/24) and the age ranged from 23 -84 years. Clinical presentation was typical sensory-motor GBS in most. Nine patients had facial palsy of which five had bilateral involvement. Two patients had bilateral abducent nerve palsy while two presented as paraparetic GBS variant with autonomic dysfunction. Electrodiagnostics studies were conducted in 17 patients only and 12 had typical features of acute inflammatory demyelinating polyradiculoneuropathy. Intravenous immunoglobulin was the preferred mode of treatment in most of the patient. There was one death, and most were discharged to rehabilitation or home. GBS is an important neurological complication associated with COVID-19. More data are needed to establish a casualty. However, most cases have a post-infectious onset with male preponderance. Most of the cases have a typical presentation but some may present atypically. The prognosis is generally good

Included in

Neurology Commons